FDA Action Shouldn’t Halt Amazon Labeling Suit, Plaintiffs Say
January 23, 2026
Shoppers accusing Amazon of failing to make required disclosures on dietary supplement product pages told a Seattle federal judge there’s no need to pause their proposed class action amid possible rulemaking by the U.S. Food and Drug Administration, arguing that the supposed rule change wouldn’t negate the suit’s claims under California law.
Search
RECENT PRESS RELEASES
Related Post
